首页> 美国卫生研究院文献>Neuropsychiatric Disease and Treatment >Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center Retrospective Case Series
【2h】

Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center Retrospective Case Series

机译:具有标准支持疗法的自闭症谱系障碍儿童的药理干预显着改善了核心迹象和症状:单中心回顾性盒系列

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with high heterogeneity and no clear common cause. Several drugs, in particular risperidone and aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment with risperidone and aripiprazole is currently recommended by the Food and Drug Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively. Here, we investigated the use of these medications in younger patients aged 4 years and older.
机译:自闭症谱系障碍(ASD)是一种衰弱的神经发育障碍,具有高异质性,并且没有明显的常见原因。几种药物,特别是Risperidone和Aripiprazole,用于治疗ASD的儿童的合并挑战性行为。目前,美国食品药品和药物管理局(FDA)分别推荐使用Risperidone和Aripiprazole的治疗分别为5岁及6岁及以上的儿童。在这里,我们调查了在4岁及以上的年轻患者中使用这些药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号